ASH 2014: Phase I study of duvelisib in indolent non-Hodgkin lymphoma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses a phase I study of the novel PI3k-δ,γ inhibitor, duvelisib (IPI-145), in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Year of Production:
Running Time:
Color/Sound:

2015
01:25
Color/Sound

Comments are closed.